0.178
-0.01 (-3.58%)
| Previous Close | 0.185 |
| Open | 0.185 |
| Volume | 417,718 |
| Avg. Volume (3M) | 1,127,908 |
| Market Cap | 4,940,906 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
| Diluted EPS (TTM) | -0.230 |
| Current Ratio (MRQ) | 7.27 |
| Operating Cash Flow (TTM) | -4.18 M |
| Levered Free Cash Flow (TTM) | -2.43 M |
| Return on Assets (TTM) | -67.76% |
| Return on Equity (TTM) | -119.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Virios Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -0.67 |
|
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.74% |
| % Held by Institutions | 3.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |